Physician profile
Laura A Eichenlaub
NPI 1063870715
$7,642.89
in general payments reported to CMS, 2019-2025
51 companies · $2,255 in 2025
The $2,255 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $980 · 2022: $732 · 2023: $1,686 · 2024: $1,990 · 2025: $2,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,683 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,682.69 |
| Education | $248.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $715.91 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Exelixis INC. | $589.10 | 2023-2025 | Cabometyx |
| Amgen INC. | $396.76 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Astrazeneca Pharmaceuticals LP | $387.58 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Pfizer INC. | $386.22 | 2021-2025 | |
| Janssen Biotech, INC. | $363.50 | 2021-2025 | Darzalex, Talvey, Erleada |
| Eisai INC. | $363.40 | 2023-2025 | |
| Daiichi Sankyo INC. | $346.99 | 2021-2025 | Enhertu, Datroway |
| Incyte Corporation | $333.38 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $316.20 | 2021-2025 | |
| Genentech USA, INC. | $267.68 | 2022-2025 | Tecentriq, Alecensa, Polivy |
| Seagen INC. | $247.94 | 2022-2025 | Tukysa, Padcev |
| Gilead Sciences, INC. | $247.89 | 2021-2025 | Trodelvy |
| Array Biopharma INC | $243.88 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $228.27 | 2022-2025 | Libtayo, Lynozyfic |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Eichenlaub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.